RBC指出，Compass Pathways股票"在强劲数据和获批前景明朗的情况下，股价可能会翻倍"，强调了即将公布的试验结果可能产生的重大影响。分析师目标价在8美元至40美元之间，共识推荐评级为1.45， InvestingPro 将该股票识别为具有高波动性（贝塔系数：1.93），并提供了10个额外的专业提示，帮助投资者把握这一临床阶段生物技术机会。

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 The ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June To date, the COMP005 trial is the largest, ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250731175223/en/ The articles, information, and content displayed on this webpage ...

LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health ...

Maxim lowered the firm’s price target on Compass Pathways (CMPS) to $12 from $22 and keeps a Buy rating on the shares. The firm cites the company having announced a delay to the data readout for the ...